The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion
- PMID: 3322911
- DOI: 10.1007/BF00296993
The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion
Abstract
The effects of porcine glucose-dependent insulinotropic polypeptide given by continuous intravenous infusion in normal subjects (n = 6) and Type 2 (non-insulin-dependent) diabetic patients (n = 6) have been investigated. The subjects were studied on 2 separate days after overnight fasts. On each day 25 g of glucose was infused from 0-30 min plus an infusion of either porcine glucose-dependent insulinotropic polypeptide (0.75 pmol . kg-1 . min-1) or control solution. During the glucose-dependent insulinotropic polypeptide infusion plasma glucose values were reduced in normal subjects from 30-60 min (p less than 0.01) and in Type 2 diabetic patients at 45 and 60 min (p less than 0.05). In the normal subjects insulin concentrations were greater from 10-35 min (p less than 0.01) following glucose-dependent insulinotropic polypeptide infusion and peak values were increased by 123%. In the Type 2 diabetic patients following glucose-dependent insulinotropic polypeptide infusion insulin levels were increased from 4-40 min (p less than 0.01) but peak values were only increased by 27%. In the normal subjects C-peptide values were greater from 25-45 min (p less than 0.01) following glucose-dependent insulinotropic polypeptide infusion and peak C-peptide levels were increased by 82%. In the Type 2 diabetic patients following the glucose-dependent insulinotropic polypeptide infusion C-peptide levels were increased from 6-55 min (p less than 0.01) and peak values were increased by 20%. Plasma glucose-dependent insulinotropic polypeptide levels were within the physiological post prandial range during the glucose-dependent insulinotropic polypeptide infusion.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.Diabetologia. 1989 Sep;32(9):668-77. doi: 10.1007/BF00274255. Diabetologia. 1989. PMID: 2676668 Clinical Trial.
-
Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus.Horm Metab Res. 1989 Jan;21(1):23-6. doi: 10.1055/s-2007-1009141. Horm Metab Res. 1989. PMID: 2647605 Clinical Trial.
-
A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.Diabetes Res Clin Pract. 1989 Nov 6;7(4):263-9. doi: 10.1016/0168-8227(89)90014-4. Diabetes Res Clin Pract. 1989. PMID: 2693029 Clinical Trial.
-
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.Dan Med J. 2016 Apr;63(4):B5230. Dan Med J. 2016. PMID: 27034187 Review.
-
On the role of the gut in diabetic hyperglucagonaemia.Dan Med J. 2017 Apr;64(4):B5340. Dan Med J. 2017. PMID: 28385175 Review.
Cited by
-
Insulin-regulated glucagon-like peptide-1 release from L cells: actin' out.Endocrinology. 2009 Dec;150(12):5202-4. doi: 10.1210/en.2009-1178. Endocrinology. 2009. PMID: 19933397 Free PMC article. No abstract available.
-
Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.Int Urol Nephrol. 2013 Dec;45(6):1733-40. doi: 10.1007/s11255-013-0457-4. Epub 2013 May 14. Int Urol Nephrol. 2013. PMID: 23670285
-
High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats.Diabetologia. 2010 Oct;53(10):2233-40. doi: 10.1007/s00125-010-1830-9. Epub 2010 Jun 30. Diabetologia. 2010. PMID: 20585935
-
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.J Clin Invest. 1993 Jan;91(1):301-7. doi: 10.1172/JCI116186. J Clin Invest. 1993. PMID: 8423228 Free PMC article. Clinical Trial.
-
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.Exp Diabetes Res. 2012;2012:470851. doi: 10.1155/2012/470851. Epub 2012 May 14. Exp Diabetes Res. 2012. PMID: 22666230 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous